Utility of Adding Once‐Weekly Hemoadsorption to High‐Volume Hemodiafiltration for Refractory Restless Legs Syndrome: A Clinical Case Report
Dialysis improves survival in kidney failure but does not effectively remove larger uremic toxins, contributing to persistent symptoms like restless legs syndrome (RLS). High-volume hemodiafiltration (HDF) has improved these issues, but refractory cases may require combined therapies with hemoadsorption (HA). We present a patient with refractory RLS treated with HDF plus hemoadsorption using Jafron HA130 cartridges. The β2 microglobulin (β2M) reduction ratio was higher during HDF+HA (76.4% [75.8-77.8] vs. 72.9% [71.1-73.2]), with further improvement at Q<sub>B</sub> > 400 ml/min (77.6% [77.2-79.4]). Despite similar baseline β2M levels, the patient's RLS score dropped from 32 to 0 points. Adding once-weekly hemoadsorption to high-volume HDF using HA130 adsorption may enhance refractory uremic symptom management, particularly at higher Q<sub>B</sub> values. Given the scarce literature on this approach, our case highlights its potential benefits for dialysis patients with persistent uremic symptoms.
Authors
- Gonzalo Ramírez‐Guerrero (ORCID: https://orcid.org/0000-0002-1696-9997)
- Cristian Pedreros‐Rosales (ORCID: https://orcid.org/0000-0002-1338-0503)
- Jonathan Alarcón‐Fuentes
- Beatriz Calderón‐Salazar
- Hans Müller‐Ortiz
Institutions
- University of Concepción (CL)
- Hospital Carlos Van Buren (CL)
- Hospital Las Higueras (CL)
Publication Details
- Journal
- Seminars in Dialysis
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1111/sdi.70014
- Primary Topic
- Restless Legs Syndrome Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00